Contineum Therapeutics, Inc. (Ticker: CTNM US) is a biotechnology company based in the United States, specializing in the discovery and development of novel, oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications, including idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The company's lead asset, PIPE-791, is a brain-penetrant, small molecule inhibitor targeting the lysophosphatidic acid 1 receptor (LPA1R), with ongoing development for both IPF and Progressive MS.

Additionally, Contineum Therapeutics is advancing PIPE-307, a novel inhibitor of the muscarinic type 1 M1 receptor (M1R), for the treatment of depression and relapsing-remitting MS (RRMS), in collaboration with Johnson & Johnson.

Established in 2009, Contineum Therapeutics’ IPO, managed by Goldman Sachs (Left Lead), Morgan Stanley, RBC Capital Markets, and Stifel, is set to occur on April 5, 2024, with the company offering 8.8 million shares priced between USD 16.00 and USD 18.00, aiming to raise approximately USD 158.4 million. The firm operates out of San Diego, California, and as of the last 12 months, reported revenues of USD 50 million and a net income of USD 22.72 million.